2ND LINE HORMONAL-THERAPY WITH AMINOGLUTETHIMIDE IN METASTATIC BREAST-CANCER

被引：10
作者：
BRUFMAN, G
BIRAN, S
机构：
[1] Department of Clinical Oncology, Hadassah University Hospital, Jerusalem
来源：
ACTA ONCOLOGICA | 1990年 / 29卷 / 06期
关键词：
Aminoglutethimide; Breast cancer; Tamoxifen;
D O I：
10.3109/02841869009092989
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide. The overall response rate was 34% and the median duration of response 9.5 months. Response to aminoglutethimide was achieved in all metastatic sites except lung and brain. Even 25% of patients who had failed to respond to prior tamoxifen did respond objectively to aminoglutethimide. The actuarial survival for all patients at 30 months was 22% Although initial toxicity was high (70% side effects of aminoglutethimide were transient, and treatment had to be discontinued in only four patients. The results of this trial confirm that aminoglutethimide is an effective treatment in metastatic breast cancer. ©1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码：717 / 720
页数：4
相关论文
共 50 条
[11]   CLINICAL CHARACTERISTICS OF 2ND PRIMARY TUMORS FOLLOWING BREAST-CANCER [J].
ROBINSON, E ;
ADLER, Z ;
NASRALLAH, S ;
RENNERT, G ;
NEUGUT, AI .
ISRAEL JOURNAL OF MEDICAL SCIENCES, 1995, 31 (2-3) :169-171
[12]   INDICATIONS FOR CYTOSTATIC THERAPY IN METASTATIC BREAST-CANCER [J].
KVINNSLAND, S .
ACTA ONCOLOGICA, 1992, 31 (02) :215-218
[13]   FAC (FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE) AS 2ND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER PROGRESSING UNDER FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) CHEMOTHERAPY [J].
CATIMEL, G ;
CHAUVIN, F ;
GUASTALLA, JP ;
REBATTU, P ;
BIRON, P ;
CLAVEL, M .
ANNALS OF ONCOLOGY, 1994, 5 (01) :95-97
[14]   AMINOGLUTETHIMIDE IN ADVANCED BREAST-CANCER - PROSPECTIVE, RANDOMIZED COMPARISON OF 2 DOSE LEVELS [J].
DELLACUNA, GR ;
PANNUTI, F ;
MARTONI, A ;
CAMAGGI, CM ;
STROCCHI, E ;
DAPRADA, GA ;
TANNEBERGER, S .
ANTICANCER RESEARCH, 1993, 13 (6B) :2367-2371
[15]   Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer [J].
Parker, LM .
CLINICAL THERAPEUTICS, 2002, 24 :C43-C57
[16]   MITOMYCIN-C AND VINORELBINE AS 2ND LINE CHEMOTHERAPY FOR METASTATIC BREAST-CARCINOMA [J].
AGOSTARA, B ;
GEBBIA, V ;
TESTA, A ;
CUSIMANO, MP ;
GEBBIA, N ;
CALLARI, AM .
TUMORI, 1994, 80 (01) :33-36
[17]   2ND-LINE HORMONOTHERAPY FOR BREAST-CANCER - USELESSNESS OF 1ST-LINE CONTINUATION [J].
PRONZATO, P ;
RUBAGOTTI, A ;
AMOROSO, D ;
BERTELLI, G ;
QUEIROLO, P ;
SERTOLI, MR ;
ROSSO, M ;
GALLOTTI, P ;
MONZEGLIO, C ;
ROSSO, R .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (06) :522-525
[18]   PROGNOSTIC FACTORS AFFECTING RESPONSE TO AMINOGLUTETHIMIDE IN ADVANCED BREAST-CANCER [J].
BRUFMAN, G .
ANTICANCER RESEARCH, 1993, 13 (04) :1235-1237
[19]   A REVIEW OF BREAST CANCER AND HORMONAL THERAPY [J].
Patel, Binal .
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2019, 10 (02) :519-527
[20]   TREATMENT OF METASTATIC - BREAST-CANCER [J].
ESPIE, M ;
MORVAN, F .
PATHOLOGIE BIOLOGIE, 1994, 42 (10) :965-966
12345